Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

India’s pharmaceutical exports rose more than 2% year on year to $31.11 billion in FY26 despite a 23% decline in March amid the fallout of the West Asia war. A new record, the exports bettered the $30.47 billion registered in 2024-25. March incidentially had played a crucial role in shaping the overall FY25 performance as shipments to the all important U.S. market surged in the face of an impending higher tariff regime.

Base year effect

In March 2026, pharma exports declined as much as 23.17% to $2,828.60 million ($3,681.66 million), official numbers showed. The downturn was largely concentrated in the final quarter, driven by logistics disruptions and tariff-related uncertainties, a highly placed source said.

Exports to the U.S, in particular, came under significant pressure, as the war disrupted shipping. U.S. tariff worries remained in 2025-26 too and there were concerns over potential tariffs on branded patented drugs manufactured outside the US. Generic medicines retain a cushion, for now, an official said.

The impact of the evolving situation was not completely unexpected. Commerce Secretary Rajesh Agrawal had told a meeting here earlier this month while “we are likely to land up better than last year,” but the $32 billion target set for FY26 is unlikely to be achieved. The performance in rupee terms may still be better given the the currency depreciation, he had said.

Pharmaceuticals Export Promotion Council of India chairman Namit Joshi, who earlier estimated the March exports to be lower anywhere between $250 million to $500 million due to the war impact, had said FY26 exports will be “somewhere near to last year achievement”. The The above normal sourcing by the U.S. in March 2025 was bound to have a bearing on the FY26 numbers, he said.

For the 11 months upto February, the exports were nearly $28.29 billion ($26.79 billion). “We have already achieved 5.6% growth upto February. March is important for us,” Pharmexcil Director General Raja Bhanu said.

With granular details of the FY26 performance expected soon, a clear picture on various aspects will emerge, including India’s emphasis on diversifying to newer markets.

Related Posts

CBI arrests two NCB staffers for demanding Rs 25 lakh bribe from a chemist in UP

CBI alleges SI Kumar disposed of the bribe amount after the transaction, and it has not been recovered yet. Two sub-inspectors posted with the Narcotics Control Bureau have been arrested…

Sakeena Itoo reviews functioning of Drug Testing Laboratory, GMC Kathua

Minister directs quality testing, optimum utilisation of medical infra Kathua: Minister for Health and Medical Education and Social Welfare, Sakeena Itoo, Monday visited the Modern Drug Testing Laboratory and Government…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CBI arrests two NCB staffers for demanding Rs 25 lakh bribe from a chemist in UP

CBI arrests two NCB staffers for demanding Rs 25 lakh bribe from a chemist in UP

Delhi Police bust fake Unani healthcare call centre in Pitampura; 12 arrested

Delhi Police bust fake Unani healthcare call centre in Pitampura; 12 arrested

Sakeena Itoo reviews functioning of Drug Testing Laboratory, GMC Kathua

Sakeena Itoo reviews functioning of Drug Testing Laboratory, GMC Kathua

Annovis Bio receives US patent covering new crystalline form of buntanetap

Annovis Bio receives US patent covering new crystalline form of buntanetap

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Bengaluru: Medical devices worth ₹13.79 lakh seized in enforcement drive

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0

Yashoda Medicity Unveils T-Shirts & Finisher Medals ahead of Yashoda Half Marathon 4.0